Can-Fite BioPharma Ltd.CANF
Price (close)
$2.16
Market cap
—
P/E
—
Revenue (FY)
$405,000
Net income
-$9.8M
Dividend yield
—
1-year total return
-82.3%
Net margin
-2426.7%
Revenue growth
-39.9%
Debt / equity
—
What Can-Fite BioPharma Ltd. does.
are an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the
treatment of cancer, liver and inflammatory diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor,
or A3AR, as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $763,000 | $853,000 | $810,000 | $743,000 | $674,000 | $405,000 |
| Net income | -$14.4M | -$12.6M | -$10.2M | -$7.6M | -$7.9M | -$9.8M |
| Free cash flow | -$12.1M | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$9.0M |
More on CANF.
- Can-Fite BioPharma Ltd. summary
- Can-Fite BioPharma Ltd. financial statements
- Can-Fite BioPharma Ltd. key metrics
- Can-Fite BioPharma Ltd. health scores and style box
- Can-Fite BioPharma Ltd. earnings
- Can-Fite BioPharma Ltd. dividends
- Can-Fite BioPharma Ltd. valuation
- Can-Fite BioPharma Ltd. ownership and insiders
- Can-Fite BioPharma Ltd. peers
Figures from Can-Fite BioPharma Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.